The text reports on financial information from Thermo Fisher Scientific Inc., presenting condensed consolidated financial statements, balance sheets, statements of income, comprehensive income, and cash flows. It highlights the company's assets, liabilities, revenues, and expenses, including various categories like cash, equities, costs, and taxes. Additionally, the information covers aspects such as amortization of intangible assets, income before taxes, geographical revenue breakdown, income taxes, debt and financing arrangements, credit facilities, earnings per share, and details on borrowing arrangements as of specific periods. Key points include the breakdown of revenues by country, income tax provision calculations, effective interest rates on debt, and details on the company's revolving credit facility and commercial paper programs.
The text outlines Thermo Fisher Scientific Inc.'s financial performance, results of operations, and critical accounting policies for the second quarter and first six months of 2023. It discusses factors impacting the company's revenues, operating income, earnings per share, and segments like Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products. It details how the company evaluates segment performance, points out recent acquisitions, liquidity, and capital resources. Additionally, it explains non-GAAP measures used by the company to provide insight into operational performance and future prospects. Finally, the text briefly touches on critical accounting policies and recent accounting pronouncements.
The company's exposure to market risk from changes in interest rates and currency exchange rates has remained consistent and has not significantly changed from the previous disclosure in the company's Annual Report on Form 10-K for the year ended December 31, 2022.
Management at the company, alongside the CEO and CFO, evaluated the effectiveness of disclosure controls and procedures as of the report period end, noting that controls can only offer reasonable assurance of achieving objectives. They concluded that controls and procedures were effective at a reasonable assurance level. Additionally, there were no significant changes in internal control over financial reporting during the quarter ended July 1, 2023, for Thermo Fisher Scientific Inc.
The text mentions that there are multiple legal proceedings against the company related to product liability, intellectual property, employment, and commercial issues. It directs the reader to refer to Note 8 in the company's financial statements for more details on these lawsuits and claims.
The text provided mentions that the material risks for investors are detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2022, under the section titled "Risk Factors," which can be found with the Securities and Exchange Commission (SEC).
The company did not engage in any share repurchase activities during the second quarter of 2023. However, on November 10, 2022, the Board of Directors approved the repurchase of up to $4.00 billion of the company's common stock. As of July 1, 2023, $1.00 billion remained available for future repurchases under this authorization.
I am ready to receive the text parts for summarization. Please go ahead and send them to me.
I'm ready to assist. Please go ahead and provide the text parts for me to summarize.
No directors or officers of the company adopted or terminated any trading arrangements during the quarterly period covered by the report.
The text includes various exhibits related to Thermo Fisher Scientific Inc., such as a Restricted Stock Unit Agreement for Directors, certifications by the Chief Executive Officer and Chief Financial Officer mandated by the Sarbanes-Oxley Act, and different XBRL documents. These exhibits are part of a report signed by Stephen Williamson, the Senior Vice President and Chief Financial Officer, and Joseph R. Holmes, the Vice President and Chief Accounting Officer, on behalf of Thermo Fisher Scientific Inc.
